SCHEDULE 13G/A: BlackRock, Inc. Maintains Significant 15.2% Stake in Pacira BioSciences, Inc.

BlackRock, Inc. has filed an amended Schedule 13G, confirming its beneficial ownership of 15.2% of Pacira BioSciences, Inc.'s common stock as of March 31, 2025.

Summary

• BlackRock, Inc. filed Amendment No. 13 to its Schedule 13G regarding its beneficial ownership in Pacira BioSciences, Inc.
• As of March 31, 2025, BlackRock, Inc. beneficially owns an aggregate of 7,017,119 shares of Pacira BioSciences, Inc. Common Stock.
• This ownership represents 15.2% of the total outstanding class of securities.
• BlackRock holds sole voting power over 6,943,981 shares and sole dispositive power over all 7,017,119 shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
• iShares Core S&P Small-Cap ETF is identified as one entity within BlackRock's structure that holds more than 5% of Pacira BioSciences, Inc.'s common stock.
• BlackRock Fund Advisors also beneficially owns 5% or greater of the outstanding shares of the security class.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing indicating a significant, stable, and passive institutional investment. While not directly positive for the company's operations, it reflects continued confidence from a major investor and provides transparency, which is generally viewed favorably.

Positives

• BlackRock, a prominent institutional investor, maintains a substantial 15.2% stake in Pacira BioSciences, Inc., signaling continued confidence in the company.
• The filing explicitly states that the shares are held in the ordinary course of business and not for control purposes, indicating a stable, passive investment by a major asset manager.

Future Outlook

The document is a routine ownership disclosure and does not contain forward-looking statements or guidance regarding Pacira BioSciences, Inc.'s future performance or BlackRock's future investment intentions beyond the certification that shares are held in the ordinary course of business.

Management Comments

• "The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

This filing is a standard disclosure of institutional ownership by a major asset manager, BlackRock, in a biotechnology company, Pacira BioSciences, Inc. It reflects BlackRock's passive investment strategy in the sector, consistent with its role as a large-scale diversified investor. Such filings are common and provide transparency on significant shareholder positions within the healthcare and pharmaceutical industry.

Comparison to Industry Standards

• As a Schedule 13G filing, this document primarily serves to disclose a significant passive ownership stake. It does not provide performance metrics for direct comparison to industry standards or specific comparable companies.
• BlackRock's 15.2% stake is a substantial position for an institutional investor, indicating a notable allocation to Pacira BioSciences, Inc. within its portfolio, which is typical for large index or actively managed funds holding positions in companies like Pacira BioSciences, Inc. (e.g., within the S&P Small-Cap index, as indicated by iShares Core S&P Small-Cap ETF's holding).

Corporate Governance

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's stake, potentially reinforcing confidence due to BlackRock's continued passive investment.
• Regulatory Authorities: Fulfills mandatory disclosure requirements, ensuring market transparency and compliance with SEC regulations.

Next Steps

• BlackRock, Inc. will continue to file amendments to Schedule 13G as required by changes in its beneficial ownership of Pacira BioSciences, Inc. Common Stock.

Key Dates

Keywords

BlackRock, Pacira BioSciences, Schedule 13G, Beneficial Ownership, Institutional Investment, Common Stock, Biotechnology, Pharmaceuticals